Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tenaya Therapeutics ( (TNYA) ) has issued an announcement.
On February 6, 2025, Tenaya Therapeutics appointed Tomohiro Higa as the Interim Principal Accounting Officer. Higa, who has been with the company since January 2025, has a rich background in finance roles at several notable biopharmaceutical companies. In a separate decision, the company’s Board of Directors approved a repricing of underwater stock options for CEO Faraz Ali, effective the same day, to better align incentives and retain key leadership without additional equity grants or cash compensation. This repricing reduces the exercise price of Ali’s options to $1.21 per share, significantly lowering it from the previous range of $5.64 to $15.19 per share.
More about Tenaya Therapeutics
Tenaya Therapeutics operates in the biopharmaceutical industry, focusing on developing therapies for heart disease.
YTD Price Performance: -29.58%
Average Trading Volume: 4,509,668
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $79.22M
See more insights into TNYA stock on TipRanks’ Stock Analysis page.
